Document Detail

The biomarker plasma galectin-3 in advanced heart failure and survival with mechanical circulatory support devices.
MedLine Citation:
PMID:  23352394     Owner:  NLM     Status:  In-Data-Review    
BACKGROUND: During screening of heart transplantation (HTx) candidates supported by ventricular assist devices (VADs) for plasma biomarkers we found that galectin-3 (Gal-3) was increased pre-operatively in patients who later died during VAD support. Therefore, we analyzed the predictive value of plasma Gal-3 in the context of other potential clinical risk factors for death on device (DOD) in a cohort of 175 VAD patients.
METHODS: We analyzed numerous clinical factors and plasma Gal-3 levels of 175 VAD patients before device implantation. Eighty VAD patients were successfully bridged to HTx (BTT, 45.7%), 80 (45.7%) died on VAD, 2 recovered on device (BTR, 1.1%) and 13 (7.4%) were still on device. Uni- and multivariate analyses were performed to assess the importance of Gal-3 with respect to other clinical factors. Myocardial gene expression of Gal-3 was investigated in apex samples by RT-PCR (n = 30) and Western blotting (n = 45).
RESULTS: Plasma Gal-3 levels were higher in VAD patients than in controls (16.6±9.3 vs 9.5±3.9 ng/ml, p < 0.0001). Cox regression showed several clinical factors and type of VAD as independent outcome predictors, but Gal-3 was not among them. Using the regression equation we grouped patients according to their factor constellation for prediction of survival on VAD. We propose a calculation method for VAD survival prediction. Gal-3 mRNA and protein were detectable in failing myocardium, but did not correlate with its plasma concentration.
CONCLUSIONS: Galectin-3 levels are associated with severe heart failure but do not provide sufficient discrimination for prediction of outcomes after VAD implantation. Importantly, we were unable to confirm myocardial tissue as a primary source for the observed plasma elevations of Gal-3.
Gülsüm Erkilet; Cenk Ozpeker; Dietmar Böthig; Frank Kramer; Daniela Röfe; Birte Bohms; Michiel Morshuis; Jan Gummert; Hendrik Milting
Related Documents :
24492114 - Genotoxicity and cytotoxicity of mineral trioxide aggregate and calcium enriched mixtur...
23157354 - Prandial ghrelin attenuation provides evidence that des-acyl ghrelin may be an artifact...
23012314 - Nitric oxide and carbon monoxide production and metabolism in preeclampsia.
24218434 - Plasma soluble (pro)renin receptor is independent of plasma renin, prorenin, and aldost...
19534624 - A patient with thyrotropinoma cosecreting growth hormone and follicle-stimulating hormo...
6815954 - The pituitary-testicular axis of uraemic subjects on haemodialysis and continuous ambul...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation     Volume:  32     ISSN:  1557-3117     ISO Abbreviation:  J. Heart Lung Transplant.     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-28     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9102703     Medline TA:  J Heart Lung Transplant     Country:  United States    
Other Details:
Languages:  eng     Pagination:  221-30     Citation Subset:  IM    
Copyright Information:
Copyright © 2013 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.
Heart and Diabetes Center NRW, Clinic of Thoracic and Cardiovascular Surgery, Erich and Hanna Klessmann-Institute for Cardiovascular Research and Development, Bad Oeynhausen.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Cognitive outcomes in pediatric heart transplant recipients bridged to transplantation with ventricu...
Next Document:  Reliability of surface electromyographic recordings during walking in individuals with knee osteoart...